Spruce Biosciences Secures Global Rights to TA-ERT, Aims For Accelerated FDA Approval In 2026

Benzinga · 04/15 11:03

Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026